AB209262

Anti-ICOS Ligand/ICOSL 抗体 [EPR20240]

Anti-ICOS Ligand/ICOSL antibody [EPR20240]

RabMAb
Recombinant
詳細を見る

Be the first to review this product! Submit a review

(5 Publications)

Rabbit Recombinant Monoclonal ICOS Ligand/ICOSL antibody. Suitable for IP, WB and reacts with Human samples. Cited in 5 publications.

別名を表示する

CD275, B7H2, B7RP1, ICOSL, KIAA0653, ICOSLG, ICOS ligand, B7 homolog 2, B7-like protein Gl50, B7-related protein 1, B7-H2, B7RP-1

4 Images

Supplier Data

Immunoprecipitation - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (AB209262)

ICOS Ligand/ICOSL was immunoprecipitated from 0.35 mg of JAR (Human placenta choriocarcinoma cell line) whole cell lysate with ab209262 at 1/40 dilution. Western blot was performed from the immunoprecipitate using ab209262 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.

Lane 1 : JAR whole cell lysate, 10 μg (Input).

Lane 2 : ab209262 IP in JAR whole cell lysate.

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab209262 in JAR whole cell lysate.

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 3 minutes.

All lanes:

Immunoprecipitation - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (ab209262)

Predicted band size: 33 kDa

Observed band size: 60 kDa

false

Supplier Data

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (AB209262)

Blocking/Dilution buffer : 5% NFDM/TBST.

The level of ICOS Ligand/ICOSL expression can be elevated by TNF-alpha treatment (PMID 11983910).

All lanes:

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (ab209262) at 1/1000 dilution

Lane 1:

Untreated HUVEC (Human umbilical vein endothelial cell line) whole cell lysate at 20 µg

Lane 2:

HUVEC whole cell lysate treated with tumor necrosis factor-α (TNF-alpha, <a href='/products/proteins-peptides/recombinant-human-tnf-alpha-protein-ab9642'>ab9642</a>) 200 unit/ml for 24 hours at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 33 kDa

Observed band size: 60 kDa

false

Exposure time: 30s

Supplier Data

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (AB209262)

Blocking/Dilution buffer : 5% NFDM/TBST.

ICOS ligand/ICOSL is highly glycosylated (PMID 11983910).

Observed band sizes : 60 kDa (glycosylated form); 35 kDa (non-glycosylated form).

All lanes:

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (ab209262) at 1/1000 dilution

Lane 1:

Untreated JAR (Human placenta choriocarcinoma cell line) whole cell lysate at 20 µg

Lane 2:

JAR whole cell lysate treated with PNGase F at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 33 kDa

false

Exposure time: 30s

Supplier Data

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (AB209262)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (ab209262) at 1/20000 dilution

All lanes:

His-tagged recombinant human ICOS ligand/ICOSL protein at 0.01 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 33 kDa

Observed band size: 50 kDa

false

Exposure time: 10s

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR20240

アイソタイプ

IgG

キャリアフリー

交差種

Human

アプリケーション

IP, WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/40", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" } } }

style

left-column

製品の詳細

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Affinity purification Protein A

バッファー組成

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

出荷温度

Blue Ice

短期保存期間

1-2 weeks

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

The ICOS Ligand also known as ICOSL B7-H2 and HK53 is a critical component in immune system function. This protein with a molecular mass of approximately 65 kDa is expressed on professional antigen-presenting cells such as dendritic cells macrophages and B cells. It plays a significant mechanical role in the immune response by engaging with its counter receptor the ICOS protein present on the surface of activated T cells. This interaction supports the regulation of T cell activity influencing proliferation and cytokine production.

Biological function summary

ICOSL contributes to the modulation of immune responses. By forming a complex with the active ICOS protein ICOSL is involved in the co-stimulation of T cells. This process is important for the development of T-cell-dependent immune responses and helps in promoting the survival and differentiation of T cells. Together the ICOS ligand and ICOS protein create a dynamic interaction that balances immune activation and tolerance which is essential for maintaining immune homeostasis.

Pathways

The ICOS-ICOSL interaction plays an important role in the T-cell receptor (TCR) signaling pathway. This pathway is fundamental for the activation of T cells and subsequent immune response. ICOSL also connects to the PI3K/Akt pathway where it impacts cell survival and proliferation. ICOS and the PI3K/Akt pathway work together to influence various aspects of immune regulation and adaptive immunity.

ICOSL has a notable impact on autoimmune diseases and cancer. Its function in immune modulation when dysregulated can contribute to autoimmune conditions such as systemic lupus erythematosus. In this context the abnormal activation of the ICOS protein may exaggerate immune responses leading to pathology. In cancer high expression of ICOSL can support tumor progression by affecting the immune surveillance capability. These associations reveal ICOSL’s role in balancing immune activation and inhibition which is important in the context of disease.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Ligand for the T-cell-specific cell surface receptor ICOS. Acts as a costimulatory signal for T-cell proliferation and cytokine secretion (PubMed : 11007762, PubMed : 11023515, PubMed : 30498080). Also induces B-cell proliferation and differentiation into plasma cells. Could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function (By similarity). In endothelial cells, required for proper neutrophil transmigration in response to chemoattractants, such as CXCL8/IL8 or N-formyl-methionyl peptides (fMLP) (PubMed : 30498080).

See full target information ICOSLG

style

left-column

文献 (5)

Recent publications for all applications. Explore the full list and refine your search

Hepatology communications 9: PubMed40366121

2025

Single-cell transcription reveals hepatocyte-to-cholangiocyte reprogramming and biliary gene profile in biliary atresia.

Applications

Unspecified application

Species

Unspecified reactive species

Lingdu Meng,Min Du,Haodong Li,Fanyang Kong,Jiajian Yang,Rui Dong,Shan Zheng,Gong Chen,Zhen Shen,Junfeng Wang

Proceedings of the National Academy of Sciences of the United States of America 121:e2408649121 PubMed38980909

2024

-targeted IcosL controls tumor rejection.

Applications

Unspecified application

Species

Unspecified reactive species

Esmerina Tili,Hajime Otsu,Teresa L Commisso,Alexey Palamarchuk,Veronica Balatti,Jean-Jacques Michaille,Gerard James Nuovo,Carlo M Croce

STAR protocols 3:101661 PubMed36097388

2022

Co-culture of primary human T cells with leukemia cells to measure regulatory T cell expansion.

Applications

Unspecified application

Species

Unspecified reactive species

Marius Külp,Laura Diehl,Halvard Bonig,Rolf Marschalek

iScience 25:104613 PubMed35800767

2022

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Marius Külp,Anna Lena Siemund,Patrizia Larghero,Alissa Dietz,Julia Alten,Gunnar Cario,Cornelia Eckert,Aurélie Caye-Eude,Hélène Cavé,Michela Bardini,Giovanni Cazzaniga,Paola De Lorenzo,Maria Grazia Valsecchi,Laura Diehl,Halvard Bonig,Claus Meyer,Rolf Marschalek

Anti-cancer drugs 33:e381-e388 PubMed34419956

2021

Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.

Applications

Unspecified application

Species

Unspecified reactive species

Jia Shi,Xuchen Dong,Wei Han,Peng Zhou,Liang Liu,Haiyang Wang,Qianqian Jiang,Haoran Li,Shan Cheng,Suwen Li,Jiaqi Yuan,Zhiyuan Qian,Jun Dong

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-ICOS Ligand/ICOSL 抗体 [EPR20240]

Anti-ICOS Ligand/ICOSL antibody [EPR20240]

Immunoprecipitation - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (AB209262)

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (AB209262)

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (AB209262)

Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (AB209262)

関連する標識済み抗体及び組成の異なる製品 (1)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

キャリアフリー

交差種

アプリケーション

免疫原

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製方法

バッファー組成

出荷温度

短期保存期間

短期保存温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (5)

代替製品

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

組合せ製品

Assay Kits

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Abcam product promise